Innovations in Tablet Coating - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Innovations in Tablet Coating
Moderated by Angie Drakulich

Pharmaceutical Technology
Volume 35, pp. s18-s23


Figure 3 (Pfizer–DEM): The Orientation Index (OI) describing the extent of a preferred orientation in the spray zone— and the resulting likelihood for poor intra-tablet coating uniformity—is shown for several tablet shapes. The mean tablet aspect ratio (A) is defined by the tablet length (L), width (W), and thickness (T). The dashed line represents the least squares linear fit to the data.
Tablet shape was found to have little effect on intertablet coating uniformity but did, however, play a role in intratablet coating uniformity due to the extent to which tablets have a preferred orientation as they pass through the spray zone. The analysis of several different tablet shapes shows a trend with an orientation index (OI)—a quantitative measure of the existence of a preferred tablet orientation in the spray zone—that correlates with a mean aspect ratio of the tablet shape (see Figure 3). Tablets with a smaller mean aspect ratio tend to have improved intratablet coating uniformity over those with a larger mean aspect ratio.

The deployment of EDEM modeling in Pfizer drug-product development has accelerated the decision-making process by predicting, before process scale-up, the performance of commercial tablet shapes at process scale. The modeling is rapid, broadly applied across the solid-drug product portfolio, and has flexibility to assess unique shape decisions early in the development process.

The value of this predictive computational tool was estimated using DoOptima software (Decision Options, LLC), which uses a market normalization process to analyze the impact on projects at various phases accounting for the typical number of projects transferring to commercial scale per year, the material, manufacturing, supplies, and labor costs associated with conducting the trial compared with the cost of the software license and resources for the simulations. The net present value of predictive modeling for film-coating scale-up was estimated at approximately $500,000 in the first year (9). Based on this success, the future focus should be to continue to advance and deploy predictive computational models to support drug product development and commercialization.

See a video demonstration from DEM Solutions here.

Section references

1. M.T. am Ende and A. Berchielli, Pharm. Develop. and Technol. 1, 47–58 (2005).

2. A. Aliseda et al., Int. J. Multiphas. Flow 34, 161–175 (2008).

3. S. Garcia-Munoz and D. Gierer, D., Int. J. Pharmaceutic. 395, 104–113 (2010).

4. W.R. Ketterhagen, Int. Jrnl. Pharmaceutic., In press (2011).

5. W.R. Ketterhagen, M.T. am Ende,and B.C. Hancock, J. Pharm. Sci. 98, 442–470 (2009).

6. K.E. Wilson and E. Crossman, Drug Development and Industrial Pharmacy 23, 1239–1243 (1997).

7. S. Tobiska and P. Kleinebudde, Eur. Jrnl. of Pharmaceutic. and Biopharmaceutic. 56, 3–9 (2003).

8. J.D. Perez-Ramos et al., AAPS PharmSciTech 6, E127–E136 (2005).

9. M.T. am Ende, B.C. Hancock and K. Huta, "An Approach for Estimating the Value of Computational Tools in Drug Product Development," presented at the AIChE Annual National Meeting, (Salt Lake City, UT, Nov. 10, 2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here